Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in children
Xiaomin Chen, Yuhua Xiao, Huiping Li, Zhi Huang, Jingyu Gao, Xinyao Zhang, Yirong Li, Bindanda Mvuama Van Timothee, Xiaoqin Feng
Abstract
Background: gene polymorphism analysis to explore the efficacy and safety of different doses of voriconazole (VCZ) for the clinical treatment of pediatric patients, with the aim of providing guidelines for individualized antifungal therapy in children. Methods: phenotype, adverse effects (AEs), and drug-drug interactions. Results: . The incidence of AEs was 25.5%, and liver function damage (46.2%) and gastrointestinal reactions (19.2%) were the most common. Conclusions: gene polymorphism has important guiding significance for individualized antifungal therapy in pediatric patients.
Topics & Concepts
CYP2C19MedicineTherapeutic drug monitoringVoriconazoleDosingGenotypingInternal medicineAdverse effectPharmacologyTrough levelDrugGenotypeGeneBiologyGeneticsTacrolimusAntifungalTransplantationMetabolismCytochrome P450DermatologyAntifungal resistance and susceptibilityMedical and Biological Ozone ResearchParasitic Diseases Research and Treatment